Jeffrey S. Hatfield
Jeffrey S. Hatfield has served as a director since April, 2017. Mr. Hatfield currently serves as Chief Executive Officer at Vividion Therapeutics, Inc., a private biopharmaceutical company focused on discovering and developing precision medicines that drug traditionally inaccessible targets. Mr. Hatfield has previously served as a chief executive officer in multiple other biotech companies, including Vitae Pharmaceuticals where he worked from 2004 to 2016. At Vitae, Mr. Hatfield successfully transitioned the company from a novel discovery platform start-up to a thriving clinical-stage, product-focused company with a robust pipeline of first-in-class programs generated from the company’s internal discovery engine. Mr. Hatfield took the company public in 2014, and in October 2016, Vitae Pharmaceuticals was acquired by Allergan plc for approximately $639 million in cash. Prior to Vitae, Mr. Hatfield worked at Bristol-Myers Squibb in a number of executive positions, including: Senior Vice President, Immunology and Virology Divisions; President and General Manager, BMS-Canada; and, Vice President, U.S. Managed Health Care. In addition to his CEO role, Mr. Hatfield also currently serves as Chairman of the Board of Directors of miRagen Therapeutics. He previously has served as a Board member at Ambit Biosciences, before its acquisition by Daiichi-Sankyo in 2015; Zafgen, Inc., before its acquisition by Larimar Therapeutics in 2020; and, the Biotechnology Innovation Organization (BIO), where he also was a member of the Board’s executive committee. Mr. Hatfield is an advisory board member for the Harvard Business School’s Blavatnik Fellowship in Life Sciences Entrepreneurship, and an adjunct professor for Purdue University’s College of Pharmacy where he teaches entrepreneurship. Mr. Hatfield holds an M.B.A. from The Wharton School, University of Pennsylvania, and a B.S. from Purdue University’s College of Pharmacy.